How many drugs treat Erythrodermic psoriasis?

Drug Landscape tracks 10 marketed treatments for Erythrodermic psoriasis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/erythrodermic-psoriasis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Erythrodermic psoriasis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erythrodermic psoriasis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Erythrodermic psoriasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Sotyktu	DEUCRAVACITINIB	Bristol-Myers Squibb	Tyrosine Kinase 2 Inhibitor [EPC]	Non-receptor tyrosine-protein kinase TYK2	2022-01-01
Spevigo	SPESOLIMAB	Boehringer Ingelheim Pharmaceuticals Inc	Interleukin-36 Receptor Antagonist [EPC]	Interleukin-1 receptor-like 2	2022-01-01
Bimzelx	BIMEKIZUMAB	Ucb Japan Co., Ltd.		Interleukin-17A	2021-01-01
Skyrizi	RISANKIZUMAB	AbbVie	Interleukin-23 Antagonist [EPC]	Interleukin-23 subunit alpha	2019-01-01
Taltz	ixekizumab	Eli Lilly	Interleukin-17A antagonist	Interleukin 17A (IL-17A) cytokine	2016-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Remicade	INFLIXIMAB	Johnson & Johnson	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	1998-01-01
Remicade	Infliximab-Dyyb	Johnson & Johnson	TNF blocker	Tumor Necrosis Factor alpha (TNFα)	1998-01-01
Trexall	methotrexate	Generic (originally Lederle Laboratories)	Antifolate, DMARD	Canalicular multispecific organic anion transporter 1, High mobility group protein B1, Multidrug resistance-associated protein 4	1953-12-07
Cimzia	Cimzia	University of Washington		Tumor necrosis factor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson · 3 drugs in Erythrodermic psoriasis
BOEHRINGER INGELHEIM PHARMACEUTICALS INC · 1 drug in Erythrodermic psoriasis
Biocad · 1 drug in Erythrodermic psoriasis
Boehringer Ingelheim Pharmaceuticals Inc · 1 drug in Erythrodermic psoriasis
Bristol-Myers Squibb · 1 drug in Erythrodermic psoriasis
Eli Lilly · 1 drug in Erythrodermic psoriasis
Generic (originally Lederle Laboratories) · 1 drug in Erythrodermic psoriasis
PFIZER INC · 1 drug in Erythrodermic psoriasis
Shanghai Biomabs Pharmaceutical Co., Ltd. · 1 drug in Erythrodermic psoriasis
UCB · 1 drug in Erythrodermic psoriasis
UCB INC · 1 drug in Erythrodermic psoriasis
Ucb Japan Co., Ltd. · 1 drug in Erythrodermic psoriasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Erythrodermic psoriasis:

Cite this brief

Drug Landscape (2026). Erythrodermic psoriasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/erythrodermic-psoriasis. Accessed 2026-06-10.

Erythrodermic psoriasis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing